New Insights into the Association between Fibrinogen and Coronary Atherosclerotic Plaque Vulnerability: An Intravascular Optical Coherence Tomography Study
Table 1
Risk factors and biochemical indices of patients according to plaque vulnerability.
Ruptured plaque group
Nonrupture with TCFA group
Nonrupture and non-TCFA group
t/χ2
P
Male
15 (88.2)
13 (86.7)
74 (60.7)
8.177
0.017
Age
58.94±10.23
55.33±9.60
56.39±12.07
0.448
0.640
Hypertension
10 (58.8)
9 (60.0)
62 (50.8)
0.749
0.688
Diabetes mellitus
10 (58.8)
8 (53.3)
24 (19.7)
15.730
<0.001
Current smoking
11 (64.7)
9 (60.0)
46 (37.7)
6.436
0.040
Current drinking
4 (23.5)
1 (6.7)
26 (21.3)
2.373
0.305
Family history
2 (11.8)
1 (6.7)
26 (21.3)
2.931
0.231
BMI
29.09±3.88
26.64±2.45
24.60±2.98
17.847
<0.001
LDL-c (mmol/l)
2.39±0.87
2.48±0.54
2.36±0.94
0.104
0.902
HDL-c (mmol/l)
0.90±0.20
1.00±0.22
1.03±0.27
2.170
0.118
ApoA1 (g/L)
1.00±0.12
1.10±0.19
1.11±0.20
2.173
0.117
ApoB (g/L)
0.78±0.28
0.83±0.19
0.8±0.52
0.033
0.968
TC (mmol/l)
3.61±0.98
3.96±0.66
3.74±1.23
0.340
0.712
TG (mmol/l)
2.08±1.02
2.26±1.33
1.94±1.61
0.299
0.742
Lp(a) (g/L)
277.22±177.78
191.92±176.26
256.05±234.49
0.641
0.543
HbA1c (%)
7.07±1.34
6.80±1.03
6.32±1.28
1.802
0.172
Uric acid (μmmol/L)
348.79±76.98
341.39±80.28
335.41±98.44
0.163
0.850
Creatinine (μmmol/L)
76.29±17.46
74.58±17.28
74.25±18.77
0.091
0.913
Carbamide (mmol/l)
5.95±1.79
4.98±1.43
5.56±1.61
1.455
0.237
eGFR
112.59±47.06
106.5±31.03
107.65±36.96
0.143
0.867
Fibrinogen (g/L)
3.71±0.54
3.27±0.40
3.56±1.06
0.840
0.434
FDP (μg/L)
1.50 (1.28, 3.35)
1.00 (0.88, 1.40)
1.50 (1.00, 2.70)
5.249
0.072
TBil (mmol/l)
11.93±3.89
12.89±4.11
13.60±10.11
0.267
0.766
DBiL (mmol/l)
2.88±1.47
3.53±1.47
3.74±2.67
0.893
0.411
IBiL (mmol/l)
9.13±3.80
9.36±4.00
9.54±5.87
0.043
0.958
PLT ^(/L)
223.12±51.27
237.6±77.93
232.33±65.22
0.214
0.808
MPV (fL)
10.31±0.75
10.43±1.38
10.75±1.08
1.676
0.191
PCT (%)
0.23±0.05
0.24±0.07
0.25±0.06
0.526
0.592
PDW
13.02±3.96
14.28±3.39
14.80±2.76
2.768
0.066
RBC(/L)
4.77±0.46
4.8±0.36
4.76±0.49
0.060
0.941
HCT (%)
0.44±0.05
0.43±0.04
0.43±0.04
0.277
0.758
HGB (g/L)
144.35±16.82
142.87±11.77
142.39±15.62
0.123
0.885
Hs-CRP
2.43 (0.82, 3.95)
0.86 (0.27, 2.15)
1.46 (0.55, 8.32)
0.831
0.660
ACS
13 (76.5)
10 (66.7)
39 (32.0)
17.105
<0.001
Aspirin
11 (64.7)
11 (73.3)
91 (74.6)
0.709
0.701
Statins
11 (64.7)
13 (86.7)
94 (77.0)
2.194
0.334
β-Blockers
7 (41.2)
3 (20.0)
46 (37.7)
2.001
0.368
ACEI/ARB
6 (35.3)
6 (40.0)
46 (37.7)
0.076
0.963
CCB
5 (29.4)
5 (33.3)
29 (23.8)
0.782
0.676
Oral hypoglycemic drugs
4 (23.5)
3 (20.0)
21 (17.2)
0.416
0.812
Insulin
2 (11.8)
1 (6.7)
13 (10.7)
0.295
0.863
Values are presented as n (%), or mean ± SD; BMI, body mass index; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; BPC-blood platelet count; MPV, mean platelet volume; PCT, thrombocytocrit; PDW, platelet distribution width; RBC, red blood cell; PLT, platelet; HCT, hematocrit; HGB, hemoglobin; TBil, total bilirubin; DBiL, direct bilirubin; IBiL, unconjugated bilirubin; SAP, stable angina pectoris; UAP, unstable angina pectoris; NSTEMI, non–ST-segment elevation myocardial infarction; Apo A1, Apo lipoprotein AI; Apo B, Apo lipoprotein B; Lp (a), Lipoprotein (a); FDP, fibrinogen degeneration products; Hs-CRP, high sensitivity C-reactive protein.
